Difference between revisions of "Histrelin (Vantas)"
Jump to navigation
Jump to search
| Line 1: | Line 1: | ||
| − | = | + | ==General information== |
| − | + | Class/mechanism: LH-RH agonist. Histrelin acetate inhibits gonadotropin secretion by desensitizing responsiveness of the pituitary gonadotropin which, in turn, causes a reduction in testicular steroidogenesis.<ref name="insert">[http://www.endo.com/File%20Library/Products/Prescribing%20Information/VANTAS.pdf Histrelin (Vantas) package insert]</ref><ref>[[Media:Histrelin.pdf | Histrelin (Vantas) package insert (locally hosted backup)]]</ref><ref>[http://www.vantasimplant.com/ Vantas implant manufacturer's website]</ref> | |
<br>Route: subcutaneous | <br>Route: subcutaneous | ||
<br>Extravasation: no information | <br>Extravasation: no information | ||
| Line 6: | Line 6: | ||
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | ||
| − | =Diseases for which it is used= | + | ==Diseases for which it is used== |
*[[Prostate cancer]] | *[[Prostate cancer]] | ||
| − | =History of changes in FDA indication= | + | ==History of changes in FDA indication== |
*10/12/2004: Initial FDA approval "in the palliative treatment of advanced [[prostate cancer]]." | *10/12/2004: Initial FDA approval "in the palliative treatment of advanced [[prostate cancer]]." | ||
Revision as of 01:44, 19 March 2017
General information
Class/mechanism: LH-RH agonist. Histrelin acetate inhibits gonadotropin secretion by desensitizing responsiveness of the pituitary gonadotropin which, in turn, causes a reduction in testicular steroidogenesis.[1][2][3]
Route: subcutaneous
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
History of changes in FDA indication
- 10/12/2004: Initial FDA approval "in the palliative treatment of advanced prostate cancer."